Literature DB >> 30608548

Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma.

Hiroki Kobayashi1, Yoshiaki Abe1, Daisuke Miura1, Kentaro Narita1, Akihiro Kitadate1, Masami Takeuchi1, Kosei Matsue1.   

Abstract

According to fluorescent in situ hybridization, t(11;14) is the most common cytogenetic abnormality in amyloid light-chain (AL) amyloidosis, but its prevalence in patients with AL amyloidosis and concurrent multiple myeloma (MM) remains unknown. We aimed to examine the prevalence of t(11;14) and the differences in clinical characteristics of patients with t(11;14) who had AL amyloidosis with or without concurrent MM. We retrospectively analyzed 40 patients with AL amyloidosis between January 2008 and January 2018 at our institution. The prevalence of t(11;14) was significantly higher in patients with AL amyloidosis alone compared with those with concurrent MM (56.5% vs. 17.6%; P = 0.022). This study suggests that AL amyloidosis patients with concurrent MM have a lower prevalence of t(11;14) than those without MM and that the presence of t(11;14) may be associated with poor prognosis, irrespective of the presence or absence of MM.

Entities:  

Mesh:

Year:  2019        PMID: 30608548     DOI: 10.1093/jjco/hyy202

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  2 in total

1.  Prognostic Factors of AL-PCMM and AL-MM: A Single-Center Retrospective Study.

Authors:  Junhui Xu; Zhixiang Qiu; Miao Yan; Bingjie Wang; Zhengyang Song; Huihui Liu; Mangju Wang; Xinan Cen
Journal:  Int J Med Sci       Date:  2022-03-14       Impact factor: 3.738

Review 2.  Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.

Authors:  Kelty R Baker
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.